Astellas seeks approval for Padcev-Keytruda combo therapy in Japan
Astellas has submitted an sNDA in Japan seeking approval for PADCEV with KEYTRUDA as a first-line treatment for advanced bladder cancer.
Astellas has submitted an sNDA in Japan seeking approval for PADCEV with KEYTRUDA as a first-line treatment for advanced bladder cancer.
What's Your Reaction?
